Table 1 Patient characteristics
From: Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites
Characteristics | Total cohort | Pre-menopausal | Post-menopausal | p-value |
|---|---|---|---|---|
| Â | n = 109 | n = 56 | n = 53 | Â |
n (%) | n (%) | n (%) | ||
Median age at assessment (years) | 51 | 45 | 58 | <0.0001 |
   Range | 22 - 76 | 22-54 | 40 - 76 |  |
Median Body Mass Index | 24 | 24 | 24 | 0.44 |
   Range | 17 - 43 | 17 - 34 | 18 - 29 |  |
T-status (TNM) | Â | Â | Â | 0.73 |
   T1 | 48 (44%) | 23 (41%) | 25 (47%) |  |
   T2 | 27 (25%) | 16 (29%) | 11 (21%) |  |
   T3 | 2 (1.8%) | 1 (1.8%) | 1 (1.9%) |  |
   Unknown | 32 (29%) | 16 (29%) | 16 (30%) |  |
N-status (TNM) | Â | Â | Â | 1.00 |
   N0 | 45 (41%) | 24 (43%) | 21 (40%) |  |
   N+ | 49 (45%) | 26 (46%) | 23 (43%) |  |
   Unknown | 15 (14%) | 6 (11%) | 9 (17%) |  |
AJCC stage (7th ed.) | Â | Â | Â | 0.87 |
   Stage I | 26 (24%) | 14 (25%) | 12 (23%) |  |
   Stage IIa | 32 (29%) | 16 (29%) | 16 (30%) |  |
   Stage IIb | 7 (6%) | 5 (9%) | 2 (4%) |  |
   Stage IIIa | 9 (8%) | 4 (7%) | 5 (9%) |  |
   Stage IIIb | 0 | 0 | 0 |  |
   Stage IIIc | 6 (6%) | 3 (5%) | 3 (6%) |  |
   Unknown | 29 (27%) | 14 (25%) | 15 (28%) |  |
Estrogen receptor | Â | Â | Â | NA |
   Positive | 93 (85%) | 50 (89%) | 43 (81%) |  |
   Unknown | 16 (15%) | 6 (11%) | 10 (19%) |  |
Progesterone receptor | Â | Â | Â | 1.00 |
   Positive | 10 (9%) | 5 (9%) | 5 (9%) |  |
   Negative | 83 (76%) | 45 (80%) | 38 (72%) |  |
   Unknown | 16 (15%) | 6 (11%) | 10 (19%) |  |
HER2 status | Â | Â | Â | 1.00 |
   Positive | 38 (35%) | 20 (36%) | 18 (34%) |  |
   Negative | 55 (50%) | 30 (54%) | 25 (47%) |  |
   Unknown | 16 (15%) | 6 (11%) | 10 (19%) |  |
Median duration of treatment (months) | 9 | 9 | 9 | 0.73 |
   Range | 2 - 70 | 2 - 59 | 3 - 70 |  |
Tamoxifen (daily dose) | Â | Â | Â | 0.17 |
   10 mg | 1 (1%) | 1 (2%) | 0 (0%) |  |
   20 mg | 102 (94%) | 50 (89%) | 52 (98%) |  |
   40 mg | 6 (6%) | 5 (9%) | 1 (2%) |  |